Glutamine Early Start in Children With SCD Younger Than Five (GLUT-5 SCD)

November 10, 2026 updated by: Fatma Soliman Elsayed Ebeid, MD, Ain Shams University

Safety and Efficacy of Glutamine in Preventing Vaso-occlusive Crisis Among Children With Sickle Cell Disease Younger Than Five

A study to assess the efficacy and safety of Glutamine in preventing Vaso Occlusive Crisis in pediatric population less than five years old

Study Overview

Status

Not yet recruiting

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Nihal H Aly, MD
  • Phone Number: +201001053961

Study Locations

      • Cairo, Egypt
        • Faculty of Medicine Ain Shams Research Institute- Clinical Research Center
        • Contact:
        • Contact:
          • Nihal H Aly, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 5 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age from 1-5 years
  • children diagnosed with SCD based on clinical picture, CBC, reticulocyte count, markers of hemolysis and hemoglobin analysis by HPLC

Exclusion Criteria:

  • Patients with clinically significant renal or liver disease
  • Patients with any clinical evidence of infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Patients receiving standard of care

Standard of care in SCD therapy as Hydroxyurea

Experimental: Patients receiving Glutamine

Standard of care in SCD therapy as Hydroxyurea

L-Glutamine as an oral powder

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of safety of L-Glutamine in children with SCD younger than 5 years old
Time Frame: 52 weeks

Assessment of safety of L-Glutamine in children with SCD younger than 5 years old by assessing the adverse event

52 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of efficacy of L-Glutamine in reducing the occurrence of VOCs
Time Frame: 52 weeks

Assessment of efficacy of L-Glutamine in reducing the occurrence of VOCs from baseline to week 52

52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Fatma SE Ebeid, MD, Faculty of Medicine Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe